• This record comes from PubMed

A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors

. 2013 Aug 08 ; 56 (15) : 6234-47. [epub] 20130724

Language English Country United States Media print-electronic

Document type Journal Article, Research Support, Non-U.S. Gov't

The inhibition of overactive CDKs during cancer remains an important strategy in cancer drug development. We synthesized and screened a novel series of 2-substituted-6-biarylmethylamino-9-cyclopentylpurine derivatives for improved CDK inhibitory activity and antiproliferative effects. One of the most potent compounds, 6b, exhibited strong cytotoxicity in the human melanoma cell line G361 that correlated with robust CDK1 and CDK2 inhibition and caspase activation. In silico modeling of 6b in the active site of CDK2 revealed a high interaction energy, which we believe is due to the 6-heterobiarylmethylamino substitution of the purine moiety.

References provided by Crossref.org

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...